SLC5A2 and metabolic dysfunction-associated steatotic liver disease: First, although several studies have proposed that SGLT2 inhibitors lower visceral fat and provide cardiovascular protection in patients with type 2 diabetes [13,14,25], this study is, as far as we know, the first to investigate the influence of SGLT2 inhibitors on whole-body fat depots and NAFLD in patients with T2D on metformin and pioglitazone maintenance therapy.